Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Cardiol. May 26, 2026; 18(5): 116478
Published online May 26, 2026. doi: 10.4330/wjc.v18.i5.116478
Published online May 26, 2026. doi: 10.4330/wjc.v18.i5.116478
Bioresorbable scaffolds in acute coronary syndrome: A promising alternative to drug-eluting stents or a step too soon?
Zainab A Dakhil, Department of Cardiology, Ibn Al-Bitar Cardiac Center/University of Baghdad, Baghdad 10003, Iraq
Author contributions: Dakhil ZA conceived the editorial focus; reviewed the evidence base; drafted and revised the manuscript; and approved the final version for submission.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Corresponding author: Zainab A Dakhil, Assistant Professor, Department of Cardiology, Ibn Al-Bitar Cardiac Center/University of Baghdad, Saleheya, Al-Naseer Street, Baghdad 10003, Iraq. stethoscope.med@gmail.com
Received: November 12, 2025
Revised: January 16, 2026
Accepted: April 7, 2026
Published online: May 26, 2026
Processing time: 188 Days and 8.4 Hours
Revised: January 16, 2026
Accepted: April 7, 2026
Published online: May 26, 2026
Processing time: 188 Days and 8.4 Hours
Core Tip
Core Tip: Bioresorbable scaffolds aim to provide temporary coronary support with drug delivery while ultimately restoring a device-free artery. In acute coronary syndrome, evidence remains cautious: First-generation polymeric scaffolds showed increased thrombosis during the resorption phase, and newer platforms require rigorous implantation discipline. The study by Li et al discussed here used the NeoVas sirolimus-eluting poly-L-lactic acid scaffold and reported comparable mid-term outcomes to drug-eluting stents, with reduced inflammatory biomarkers at 1 month. These signals are hypothesis-generating; definitive adoption requires randomized trials with imaging and long-term follow-up.